BioSpace News Archive

The Global Virus Network (GVN), a coalition comprised of the world’s preeminent human and animal virologists from 55 Centers of Excellence and 10 Affiliates in 33 countries, announced that the Peter Doherty Institute for Infection and Immunity in Melbourne,

Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief Executive Officer, will participate in a fireside chat at the JMP Securities CNS Forum, being held virtually on August 19 - 20, 2020. Presentation Details Date: Thursday, August 20, 2020 Time:

A global leader in the healthcare industry, McKesson Corporation (NYSE: MCK) will expand its existing partnership with the Centers for Disease Control (CDC) to support the U.S. government’s Operation Warp Speed (OWS) team as a centralized distributor of future COVID-19 vaccines and ancillary supplies needed to administer vaccinations.

Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company using its proprietary RADR ® artificial intelligence (“A.I.”) platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, today announced that an interview with its CEO and President Pa

Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 36,000 shares of the company’s common stock, at a per share exercise price of $3.78, the closing trading price on August 7, and restricted stock units to acquire 18,000 shares of the company’s common stock.

Kaiser Permanente study found risk of death from COVID-19 for those who are obese is higher for men and young people

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the second quarter ended June 30, 2020. AgeX made strides with respect to its newly established licensing and collaboration model, which aims to embed its technology platforms across the cell therapy industry. AgeX has entered into a rese

Financials for First Quarter of Fiscal Year 2021 ended June 30, 2020 will be released August 14, 2020

Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its Board of Directors (the “Board”) adopted a tax benefits preservation plan (the “Section 382 Rights Plan”) designed to protect the availability of Enzon’s net operating loss carryforwards (“NOLs”) under the Internal Revenue Code (the “Code”).

Eve & Co Incorporated (the “Company” or “Eve & Co”) (TSX-V: EVE; OTCQX: EEVVF) is pleased to announce its financial results for the three and six months ended June 30, 2020.